Literature DB >> 18765742

Vaccination of mice with a Yop translocon complex elicits antibodies that are protective against infection with F1- Yersinia pestis.

Maya I Ivanov1, Betty L Noel, Ryan Rampersaud, Patricio Mena, Jorge L Benach, James B Bliska.   

Abstract

Yersinia pestis, the bacterial agent of plague, secretes several proteins important for pathogenesis or host protection. The F1 protein forms a capsule on the bacterial cell surface and is a well-characterized protective antigen but is not essential for virulence. A type III secretion system that is essential for virulence exports Yop proteins, which function as antiphagocytic or anti-inflammatory factors. Yop effectors (e.g., YopE) are delivered across the host cell plasma membrane by a translocon, composed of YopB and YopD. Complexes of YopB, YopD, and YopE (BDE) secreted by Yersinia pseudotuberculosis were purified by affinity chromatography and used as immunogens to determine if antibodies to the translocon could provide protection against Y. pestis in mice. Mice vaccinated with BDE generated high-titer immunoglobulin G antibodies specific for BDE, as shown by enzyme-linked immunosorbent assay and immunoblotting, and were protected against lethal intravenous challenge with F1(-) but not F1(+) Y. pestis. Mice passively immunized with anti-BDE serum were protected from lethal challenge with F1(-) Y. pestis. The YopB protein or a complex of YopB and YopD (BD) was purified and determined by vaccination to be immunogenic in mice. Mice actively vaccinated with BD or passively vaccinated with anti-BD serum were protected against lethal challenge with F1(-) Y. pestis. These results indicate that anti-translocon antibodies can be used as immunotherapy to treat infections by F1(-) Y. pestis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18765742      PMCID: PMC2573372          DOI: 10.1128/IAI.00189-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  52 in total

1.  The RhoGAP activity of the Yersinia pseudotuberculosis cytotoxin YopE is required for antiphagocytic function and virulence.

Authors:  D S Black; J B Bliska
Journal:  Mol Microbiol       Date:  2000-08       Impact factor: 3.501

2.  Role of Yops and adhesins in resistance of Yersinia enterocolitica to phagocytosis.

Authors:  Nadine Grosdent; Isabelle Maridonneau-Parini; Marie-Paule Sory; Guy R Cornelis
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

Review 3.  Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen).

Authors:  Robert R Brubaker
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

Review 4.  Yersinia pestis (plague) vaccines.

Authors:  Richard W Titball; E Diane Williamson
Journal:  Expert Opin Biol Ther       Date:  2004-06       Impact factor: 4.388

Review 5.  Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Authors:  T V Inglesby; D T Dennis; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; A M Friedlander; J Hauer; J F Koerner; M Layton; J McDade; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; M Schoch-Spana; K Tonat
Journal:  JAMA       Date:  2000-05-03       Impact factor: 56.272

6.  Structure-function analysis of Yersinia pestis YopM's interaction with alpha-thrombin to rule on its significance in systemic plague and to model YopM's mechanism of binding host proteins.

Authors:  J Hines; E Skrzypek; A V Kajava; S C Straley
Journal:  Microb Pathog       Date:  2001-04       Impact factor: 3.738

7.  Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine.

Authors:  K R Turbyfill; A B Hartman; E V Oaks
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

8.  Anti-V antigen antibody protects macrophages from Yersinia pestis -induced cell death and promotes phagocytosis.

Authors:  S Weeks; J Hill; A Friedlander; S Welkos
Journal:  Microb Pathog       Date:  2002-05       Impact factor: 3.738

9.  Biogenesis of the fraction 1 capsule and analysis of the ultrastructure of Yersinia pestis.

Authors:  Lisa M Runco; Selina Myrczek; James B Bliska; David G Thanassi
Journal:  J Bacteriol       Date:  2008-02-29       Impact factor: 3.490

10.  Caspase-1 activation in macrophages infected with Yersinia pestis KIM requires the type III secretion system effector YopJ.

Authors:  Sarit Lilo; Ying Zheng; James B Bliska
Journal:  Infect Immun       Date:  2008-06-16       Impact factor: 3.441

View more
  20 in total

Review 1.  Surface organelles assembled by secretion systems of Gram-negative bacteria: diversity in structure and function.

Authors:  David G Thanassi; James B Bliska; Peter J Christie
Journal:  FEMS Microbiol Rev       Date:  2012-05-24       Impact factor: 16.408

2.  Translocators YopB and YopD from Yersinia enterocolitica form a multimeric integral membrane complex in eukaryotic cell membranes.

Authors:  Caroline Montagner; Christian Arquint; Guy R Cornelis
Journal:  J Bacteriol       Date:  2011-10-14       Impact factor: 3.490

Review 3.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

4.  YopD self-assembly and binding to LcrV facilitate type III secretion activity by Yersinia pseudotuberculosis.

Authors:  Tiago R D Costa; Petra J Edqvist; Jeanette E Bröms; Monika K Ahlund; Ake Forsberg; Matthew S Francis
Journal:  J Biol Chem       Date:  2010-06-04       Impact factor: 5.157

5.  Association and evidence for linked recognition of type IV secretion system proteins VirB9-1, VirB9-2, and VirB10 in Anaplasma marginale.

Authors:  Kaitlyn Morse; Junzo Norimine; Guy H Palmer; Eric L Sutten; Timothy V Baszler; Wendy C Brown
Journal:  Infect Immun       Date:  2011-10-28       Impact factor: 3.441

6.  Translocation of surface-localized effectors in type III secretion.

Authors:  Karen Akopyan; Tomas Edgren; Helen Wang-Edgren; Roland Rosqvist; Anna Fahlgren; Hans Wolf-Watz; Maria Fallman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

7.  LcrV mutants that abolish Yersinia type III injectisome function.

Authors:  Katherine Given Ligtenberg; Nathan C Miller; Anthony Mitchell; Gregory V Plano; Olaf Schneewind
Journal:  J Bacteriol       Date:  2012-12-07       Impact factor: 3.490

8.  Yersinia pestis can bypass protective antibodies to LcrV and activation with gamma interferon to survive and induce apoptosis in murine macrophages.

Authors:  Betty L Noel; Sarit Lilo; Daniel Capurso; Jim Hill; James B Bliska
Journal:  Clin Vaccine Immunol       Date:  2009-08-26

9.  High-throughput identification of new protective antigens from a Yersinia pestis live vaccine by enzyme-linked immunospot assay.

Authors:  Bei Li; Lei Zhou; JingYu Guo; Xiaoyi Wang; Bin Ni; Yuehua Ke; Ziwen Zhu; Zhaobiao Guo; Ruifu Yang
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

10.  Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague.

Authors:  Nicholas A Eisele; Deborah M Anderson
Journal:  Clin Vaccine Immunol       Date:  2009-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.